Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Inflammatory Bowel Disease: full-pipeline trial registry
12 of 29 indexed Inflammatory Bowel Disease trials are currently recruiting.
Corpus placement: #552 of 28,707 conditions by registered trial count.
29 US clinical trials · 12 currently recruiting · #552 of 28,707 conditions by registered trial count
Inflammatory Bowel Disease: 29 US clinical trials tracked, 12 recruiting.
Inflammatory Bowel Disease is the subject of 29 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Icahn School of Medicine at Mount Sinai, running 3 of these trials.
Enrollment posture brief
Registry condition inflammatory-bowel-disease
OPEN 12 | RECR 41% | LATE 5 | EARLY 5 | RANK #552 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Dyslipidemias (41% recruiting · 29 trials)
Inflammatory Bowel Disease lists 12 open slots (41% of 29 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Inflammatory Bowel Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Inflammatory Bowel Disease recruits in line with its size-band peers.
12 of 29 indexed trials (41.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Inflammatory Bowel Disease trials is spread across many organizations.
Icahn School of Medicine at Mount Sinai accounts for 3 of 29 trials (10.3%). 24 distinct sponsors appear on at least one study for this condition label.
-
Typical Inflammatory Bowel Disease enrolment sits around 105 participants.
Median target enrolment is 105 among the 29 trials that report a genuine target (sentinel values excluded). 14 of those (48.3%) plan for fewer than 100 participants.
-
Inflammatory Bowel Disease splits between interventional and observational designs.
20 interventional and 9 observational studies make up this index (69% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
29 total, page 1 of 1
A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease
University of California, San Francisco
NCT00904878
Immune Regulation in Ulcerative Colitis or Crohn s Disease
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001184
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
National Cancer Institute (NCI)
NCT03816345
Testing the Impact of Measurement-Based Care on Quality of Life and Disease Management Among Veterans With Inflammatory Bowel Disease
VA Office of Research and Development
NCT07210580
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
M.D. Anderson Cancer Center
NCT04751396
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
Massachusetts General Hospital
NCT04508088
Effect of Mediterranean Diet in Inflammatory Bowel Disease
University of California, San Diego
NCT05973500
The Influence of a Fasting Mimicking Diet on Ulcerative Colitis
Stanford University
NCT03615690
High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
Boston Children's Hospital
NCT04331639
Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation
Icahn School of Medicine at Mount Sinai
NCT06001450
Impact of Morning Light Therapy in IBD
Icahn School of Medicine at Mount Sinai
NCT07207200
A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis
Rush University Medical Center
NCT05579392
Johns Hopkins Crohn's Disease and Ulcerative Colitis Study
Johns Hopkins University
NCT01169207
Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS)
Johns Hopkins University
NCT01169194
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Janssen Research & Development
NCT01369329
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
Bausch Health Americas
NCT00486031
Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)
University of Maryland, Baltimore
NCT01692743
Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life
Icahn School of Medicine at Mount Sinai
NCT02322307
Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD
Shield Therapeutics
NCT02680756
Value of Fecal Calprotectin
Indiana University
NCT00577928
Improving Medication Adherence in Pediatric Inflammatory Bowel Disease
Children's Hospital Medical Center, Cincinnati
NCT01536509
A Trial of Rosiglitazone for Ulcerative Colitis
James Lewis
NCT00065065
Dietary Treatment of Crohn's Disease
Rush University Medical Center
NCT00343642
Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease
Cedars-Sinai Medical Center
NCT00829595
Ulcerative Colitis Relapse Prevention Trial, Hypnosis
Northwestern University
NCT00798642
Treatment of Depressed Adolescents With Physical Illness
University of Pittsburgh
NCT00446238
Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
Mayo Clinic
NCT01034358
Early Serum Infliximab Levels in Severe Ulcerative Colitis.
University of California, San Francisco
NCT01971814
A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis
University of Minnesota
NCT02464020
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 4 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Inflammatory Bowel Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Inflammatory Bowel Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Inflammatory Bowel Disease page
29 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Inflammatory Bowel Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Icahn School of Medicine at Mount Sinai sponsors the most Inflammatory Bowel Disease trials on record, review their full trial history before evaluating a specific study. See Icahn School of Medicine at Mount Sinai's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Inflammatory Bowel Disease condition card totals 29 registered trials; most-linked intervention Balsalazide Disodium; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.